In Marsh v. Genetech, Inc., the Sixth Circuit held that clever pleading of state law fraud-on-the-FDA claims could not get around its precedent on preemption of those claims.  The plaintiff claimed that Genetech did not comply with the FDA’s reporting requirements about the dangerous side effects of its psoriasis drug Raptiva.  Genetech claimed immunity under Michigan’s … Continue Reading